Toll Free: 1-888-928-9744

Selvita S.A - Product Pipeline Review - 2014

Published: Apr, 2014 | Pages: 41 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Selvita S.A - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Selvita S.A - Product Pipeline Review - 2014', provides an overview of the Selvita S.A's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Selvita S.A's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Selvita S.A including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Selvita S.A's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Selvita S.A's pipeline products

Reasons to buy

- Evaluate Selvita S.A's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Selvita S.A in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Selvita S.A's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Selvita S.A and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Selvita S.A
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Selvita S.A and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Selvita S.A Snapshot 5
Selvita S.A Overview 5
Key Information 5
Key Facts 5
Selvita S.A - Research and Development Overview 6
Key Therapeutic Areas 6
Selvita S.A - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Selvita S.A - Pipeline Products Glance 12
Selvita S.A - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Selvita S.A - Drug Profiles 14
SEL-103194 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
SEL-120 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
SEL-12034 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
SEL-141 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
SEL-24 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
SEL-24-A1 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
SEL-24-B 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
SEL24-B489 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
SLV-2436 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Drugs to Inhibit Heme Oxygenase-1 for Cancer 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Drugs to Inhibit Kinase for Cancer 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
SEL-128 Program 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
SEL-201 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
SEL-203 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SEL-212 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
SEL-300 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Selvita S.A - Pipeline Analysis 31
Selvita S.A - Pipeline Products by Target 31
Selvita S.A - Pipeline Products by Route of Administration 33
Selvita S.A - Pipeline Products by Molecule Type 34
Selvita S.A - Pipeline Products by Mechanism of Action 35
Selvita S.A - Recent Pipeline Updates 37
Selvita S.A - Discontinued Pipeline Products 38
Discontinued Pipeline Product Profiles 38
SEL-103 38
Selvita S.A - Locations And Subsidiaries 39
Head Office 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41
List of Tables
Selvita S.A, Key Information 5
Selvita S.A, Key Facts 5
Selvita S.A - Pipeline by Indication, 2014 8
Selvita S.A - Pipeline by Stage of Development, 2014 10
Selvita S.A - Monotherapy Products in Pipeline, 2014 11
Selvita S.A - Preclinical, 2014 12
Selvita S.A - Discovery, 2014 13
Selvita S.A - Pipeline by Target, 2014 32
Selvita S.A - Pipeline by Route of Administration, 2014 33
Selvita S.A - Pipeline by Molecule Type, 2014 34
Selvita S.A - Pipeline Products by Mechanism of Action, 2014 36
Selvita S.A - Recent Pipeline Updates, 2014 37
Selvita S.A - Discontinued Pipeline Products, 2014 38 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify